Catherine Penny, partner, and Laura Beagrie, professional support lawyer, Stevens & Bolton, consider an important issue brought to light by the scramble for cor 12 March 2021
Patrick Delavault, executive VP, scientific & medical affairs, LFB Biopharmaceuticals, provides an Expert View on how the pandemic has led to a focus on an impo 5 March 2021
Ambreen Farook, senior director, alliance management and program lead at Halozyme Therapeutics, provides an Expert View on the dos and don'ts of biopharmaceutic 23 February 2021
The recent merger of Mylan and Upjohn was one of the biggest in healthcare. But in their rebirth as Viatris (Nasdaq: VTRS), a lesson about the future of the ind 19 February 2021
Sarah Ellson, co-head of regulatory and life sciences and healthcare lawyer, Fieldfisher and her colleague Laura Penny, associate and regulatory lawyer, provide 8 February 2021
COVID-19 has disrupted the traditional engagement model and demands a fundamental rethink of how pharma companies engage with their customers. But few players s 28 January 2021
Novartis’ Steven Baert, chief people and organization officer, and Elizabeth Theophille, chief technology transformation officer, provide an Expert View predict 19 January 2021
Clive Glover, director, strategy, Pall Corporation, provides an Expert View on what recent developments mean for the industry and the importance of safety in ge 10 December 2020
Lawsuits for patent infringement require a showing that an accused product or process includes each and every element of an asserted claim, write Jonathan Roses 20 November 2020
As the coronavirus pandemic continues, the previously out-of-favor global biotech and life sciences sector is seeing significant investment and a reputational b 4 November 2020
Jonathan Roses, counsel Wolf, Greenfield & Sacks and Matthew Birkett, partner, Hoffmann Eitle, provide an Expert View on general treatment of salt and polymorph 23 October 2020
Japan remains on balance an attractive pharmaceutical market, with favorable volume dynamics, generally attractive pricing and broad and unfettered market acces 7 October 2020
An Expert View from Karen Noonan at the Association of Clinical Research Organizations (ACRO) on adopting a more flexible approach to trials moving forward, som 28 September 2020
An Expert View from Jonathan Roses (pictured, left), counsel, Wolf, Greenfield & Sacks, and Matthew Birkett, partner, Hoffmann Eitle, on the granting of two pat 22 September 2020
Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape.many cancer patients are still left behind.Not every 10 September 2020
Just six months into the deadliest global pandemic for a century, the way we live has changed dramatically, most likely forever. For all of us, our children, yo 7 September 2020
In these times especially, but far from exclusively, security of supply remains one of the biggest challenges for pharmaceuticals manufacturers, writes Justin E 27 August 2020
Media headlines are full of hope for potential vaccines and treatments to target SARS-CoV-2, the virus that causes the novel coronavirus disease COVID-19, write 21 August 2020
Pierre-Georges Roy, partner at M&A advisor Results International, provides an Expert View on why deals kept being made even as much of society shut down. 18 August 2020
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.